Core Viewpoint - Tango Therapeutics, Inc. is actively participating in multiple investment bank conferences to showcase its advancements in precision cancer medicines and engage with investors [1]. Group 1: Upcoming Conferences - Tango Therapeutics management will participate in the B Riley Precision Oncology & Radiopharma Conference in New York, NY in late February [1]. - The Leerink Global Healthcare Conference and Barclays 27th Annual Global Healthcare Conference will take place in Miami, FL in March [1]. - The company will be available for 1x1 meetings on Thursday, March 13 [2]. Group 2: Webcast Information - Live webcasts for each event will be available under the "Events & Presentations" tab on the company's website on the day of the event [2]. - A replay of the webcasts will be archived on the company's website for 90 days following the presentations [2]. Group 3: Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision medicine for cancer treatment [4]. - The company utilizes the genetic principle of synthetic lethality to identify and develop therapies targeting critical cancer-related pathways [4].

Core Insights - Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision cancer medicines [1][3] - The company will participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on February 5, 2025 [1] - The event will be accessible via a live webcast and will be archived for 90 days on the company's website [2] Company Overview - Tango Therapeutics is dedicated to discovering novel drug targets and precision medicine for cancer treatment [3] - The company employs the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related targets [3] - More information about the company can be found on their website [3]

Earnings season has begun, and I managed to find a few nuances in Tango Therapeutics (NASDAQ: TNGX ) that motivated me to take a long position via long options on thisHi, I'm Martin, I focus on maintaining a delta neutral portfolio. I want to be long/short at the same time and benefit from market volatility. I specialize in using options through which I enter and exit trades. I look for market opportunities primarily in small companies, and my search takes me into the waters of mid-sized companies as well.A ...

Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.59%. A quarter ago, it was expected that this company would post a loss of $0.34 per share when it actually produced a loss of $0.24, delivering a surprise of 29.41%.Over the last four quarters, the company has ...

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights – Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – Next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, TNG456, planned to enter the ...

Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 29.41%. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.35, delivering a surprise of -12.90%. Over the last four quarters, the company ...

Core Viewpoint - The market anticipates Tango Therapeutics, Inc. (TNGX) will report a year-over-year decline in earnings due to lower revenues, with actual results being crucial for stock price movement [1]. Revenue Expectations - Revenues for the upcoming quarter are projected to be $7.39 million, reflecting a significant decrease of 49.4% compared to the same quarter last year [2]. Earnings Estimates and Revisions - The consensus EPS estimate for Tango Therapeutics has been revised down by 2.76% over the last 30 days, indicating a reassessment by analysts [9]. - The Most Accurate Estimate for Tango Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -7.39%, suggesting a bearish outlook on the company's earnings prospects [22]. Earnings Performance History - Over the last four quarters, Tango Therapeutics has beaten consensus EPS estimates twice, but the company is not currently viewed as a strong candidate for an earnings beat [12][24]. Industry Context - In comparison, Blueprint Medicines (BPMC), another player in the biomedical and genetics industry, is expected to report a loss of $1.28 per share, which represents a year-over-year change of +41.6%, with revenues anticipated to be $104.55 million, up 81.6% from the previous year [31].

Tango Therapeutics, Inc. (TNGX) shares soared 6.7% in the last trading session to close at $9.89. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8.2% loss over the past four weeks. This company is expected to post quarterly loss of $0.34 per share in its upcoming report, which represents a year-over-year change of -47.8%. Revenues are expected to be $7.39 million, down 49.4% from the year-ago quarter. For Tango Therapeutics, the ...

Company Overview - Tango Therapeutics, Inc. (TNGX) shares experienced a rally of 10.3% in the last trading session, closing at $8.39, attributed to notable trading volume exceeding typical levels [4] - The company is expected to report a quarterly loss of $0.33 per share, reflecting a year-over-year change of -43.5%, with revenues projected at $7.66 million, down 47.5% from the previous year [5] Financial Performance - Last month, the company announced strong financial results for Q1 2024 and provided updates on its pipeline candidates for cancer treatment, with several clinical milestones anticipated later in 2024 [1] - The consensus EPS estimate for Tango Therapeutics has been revised 2.4% higher over the last 30 days, indicating a positive trend in earnings estimate revisions, which typically correlates with price appreciation [6] Industry Context - Tango Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where Lexicon Pharmaceuticals (LXRX), another company in the same sector, closed 4.2% lower at $1.83 and has returned -1.6% over the past month [7] - The correlation between earnings estimate revisions and near-term stock price movements is highlighted, emphasizing the importance of these trends in evaluating stock potential [2]

https://news.cision.com/medivir/r/medivir-s-licensee--tango-therapeutics--has-discontinued-development-of-its- tng348-clinical-program,c3987012 STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being ...